Navigation Links
Nation's Largest Healthcare Alliance Adds Roche HIV-1 Test to Existing Contract
Date:10/12/2007

Premier offers new Roche assay as its only real-time PCR test for HIV

INDIANAPOLIS, Oct. 12 /PRNewswire/ -- Premier Inc., the nation's largest healthcare alliance, gave its 1,700 hospital members access in August to the Roche COBAS(R) Ampliprep/COBAS(R) TaqMan(R) HIV-1 assay -- the only real-time PCR test for HIV offered to its members.

Premier added the new HIV-1 monitoring test, COBAS(R) TaqMan(R) 48 Analyzer and COBAS(R) TaqMan(R) Analyzer to its existing three-year molecular contract so that customers could combine the COBAS(R) Ampliprep, which was included in the existing molecular contract, with the COBAS(R) TaqMan(R) and the docking station to experience full automation.

"Adding the Roche HIV-1 monitoring test to Premier's menu is consistent with our mission to quickly roll out the highest level of innovation to our customers," said John Biggers, Group Vice President of Sourcing at Premier. "Premier also added COBAS(R) Taqman(R) 48 Analyzer, COBAS(R) Taqman(R) Analyzer and Roche's unique docking station so that customers could take advantage of the test's full automation while offering to their patients the most advanced HIV-1 monitoring assay based on 11 years of experience in HIV monitoring."

Roche introduced the fully automated COBAS(R) Ampliprep/COBAS(R) TaqMan(R) in response to customers' needs for a system that could allow their molecular laboratory technicians to load samples and walk away, not returning until the sample results are ready.

"Molecular technicians are in high demand," said Susan Zienowicz, Vice President for Molecular Diagnostics of Roche Diagnostics. "In creating the COBAS(R) Ampliprep/COBAS(R) TaqMan(R) HIV-1 assay, we provide labs with another strategy to help them leverage their employees' time and get more done in the lab."

About Premier Inc.

Serving 1,700 hospitals and more than 47,000 other healthcare sites, Premier is the largest healthcare alliance in the United States dedicated to improving patient outcomes while safely reducing the cost of care. Owned by not-for profit hospitals, Premier operates the nation's largest healthcare purchasing network, the most comprehensive repository of hospital clinical and financial information and one of the largest policy-holder owned, hospital professional liability risk-retention groups in healthcare. Headquartered in San Diego, Premier has offices in Charlotte, N.C. Philadelphia and Washington. For more information, visit http://www.premierinc.com.

About Roche and the Roche Diagnostics Division

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is a world leader in diagnostics, the leading supplier of drugs for cancer and transplantation and a market leader in virology. In 2006, sales by the Pharmaceuticals Division totaled 33.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.7 billion Swiss francs. Roche employs roughly 75,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai Roche's Diagnostics Division offers a uniquely broad product portfolio and supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories world-wide. For further information, please visit our Web site http://www.roche-diagnostics.us.

All trademarks used or mentioned in this release are legally protected by law.

For further information please contact:

Lori McLaughlin

Corporate Communications

317.521.3112

lori.mclaughlin@roche.com


'/>"/>
SOURCE Roche Diagnostics
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Roche offers HIV drug expertise to poor nations
2. Drug Combinations May Boost Stroke Risk
3. The Link Between Childhood Vaccinations And Diabetes Questioned
4. Research finds new explanations for dyslexia
5. Myth Of Childhood Vaccinations Linked To Increased Hospitalization Busted
6. Breast Cancer Examinations To Be Reviewed In Irish Hospitals
7. Asian Nations Told To Ready Themselves For Pandemic
8. Asian Nations To Take Joint Efforts Against H5N1
9. Media Plays Crucial Role In Flu Vaccinations
10. Drug Combinations Could Be Dangerous
11. Pediatricians Resignations Cause Concern at Sale
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... York, NY (PRWEB) , ... January 20, 2017 ... ... – VW+ 001 and its sugar-free alternative VW+ 002. The drinks have been ... body with optimal conditions to perform during your workout. , After a successful ...
(Date:1/20/2017)... ... January 20, 2017 , ... D R ... Pressure (OPEP) device, was featured in a study indicating superior performance against competitive ... “Analysis of Three Oscillating Positive Expiratory Pressure Devices During Simulated Breathing“ was ...
(Date:1/20/2017)... ... 2017 , ... “God's Miracle Man: Against All Odds”: an inspiring affirmation ... author, Keith C. A. Tucker, son of Minister Delores Pinnock and a Jamaican native ... Mark Hardy , “While sitting up in bed, I felt a pounding headache. It ...
(Date:1/19/2017)... ... January 19, 2017 , ... With the cold weather here, many people will have to clear ... when clearing large amounts of snow, but they can be dangerous when used incorrectly. That’s ... Safety Commission for the proper use of snow blowers:, , When ...
(Date:1/19/2017)... ... January 19, 2017 , ... Cosmetic Town, an online plastic ... in order to make it easier for their readers to get the information they ... impact as well as the techniques used on those particular areas. , “We are ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... YORK , Jan. 19, 2017 ... USD 233.7 billion by 2025, according to a ... market is anticipated to be predominantly driven by ... resulting into the large-scale production of new and ... the influx of drugs at an unprecedented rate ...
(Date:1/19/2017)... 19, 2017 Conference Call and Webcast to Follow ... announced it will release results for the fourth quarter of 2016 ... ... conference call at 4:30 PM ET on Wednesday, February 15, 2017, ... 2016 financial results and other corporate activities. To participate in the ...
(Date:1/19/2017)... , Jan. 19, 2017  Stealth BioTherapeutics Inc. ... to treat mitochondrial dysfunction, today announced new additions to ... M.D., as Chief Medical Officer, and Daniel Geffken ... announced that Jim Carr , Pharm.D. has been ... "We are pleased to welcome Doug and Daniel to ...
Breaking Medicine Technology: